We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Naïve Human Stem Cells to Promote Research in Regenerative Medicine and Human Development

By LabMedica International staff writers
Posted on 14 Nov 2013
Discovery of a method for maintaining human induced pluripotent stem cells (iPS cells) in their earliest, most primitive, naïve state is expected to promote research into their use in regenerative medicine, patient-specific iPS cell disease modeling, and the study of early human development in vitro and in vivo.

Induced pluripotent stem cells are usually created by inserting four genes into the genomes of such adult cells as skin cells and then culturing the modified cells with a cocktail of growth factors. More...
The differentiated cells then revert to an embryonic-stem-cell-like state from which they can mature into a multitude of different cell types. The problem has been the lack of a method to hold the stem cells in the undifferentiated state for any length of time.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) worked on this problem with both mouse and human cells. In particular, they were interested in establishing a technique to preserve human iPS cells in their earliest, naïve state that would mimic the behavior of mouse stem cells, which naturally remain in an undifferentiated state for much longer.

They reported in the October 30, 2013, online edition of the journal Nature that they had successfully established defined conditions that facilitated the derivation of genetically unmodified human naive pluripotent stem cells from already established primed human embryonic stem cells, from somatic cells through iPS cell reprogramming, or directly from blastocysts. The novel naïve pluripotent cells retained molecular characteristics and functional properties that were highly similar to mouse naive embryonic stem cells, and distinct from conventional primed human pluripotent cells.

"These cells correspond to the earliest stages of human embryonic stem cells that have been isolated. We managed to freeze what is essentially a very fleeting situation and to produce a new, naïve, pluripotent state in stem cells," said senior author Dr. Jacob H. Hanna, professor of medical genetics at the Weizmann Institute of Science. "When we grow the cells in the petri dish we do not know if they are maintaining their original state as in the embryo. This is what is new: this is the first time that we can keep the cells in what we call the naïve configuration. The challenge for us now is how to take these naïve cells and in the petri dish make a liver, or, from our study, it starts creating the possibility that with these cells you may consider growing organs in other species. We do not know if that works. There are a lot of ethical issues to consider. But we have put this on the table."

Related Links:

Weizmann Institute of Science



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Laboratory Software
ArtelWare
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.